GENFIT (GNFT) Competitors $3.87 -0.19 (-4.68%) As of 08/29/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GNFT vs. AVBP, SANA, GYRE, OCS, DNA, ATAI, IMTX, TNGX, BGM, and MNMDShould you be buying GENFIT stock or one of its competitors? The main competitors of GENFIT include ArriVent BioPharma (AVBP), Sana Biotechnology (SANA), Gyre Therapeutics (GYRE), Oculis (OCS), Ginkgo Bioworks (DNA), atai Life Sciences (ATAI), Immatics (IMTX), Tango Therapeutics (TNGX), BGM Group (BGM), and Mind Medicine (MindMed) (MNMD). These companies are all part of the "pharmaceutical products" industry. GENFIT vs. Its Competitors ArriVent BioPharma Sana Biotechnology Gyre Therapeutics Oculis Ginkgo Bioworks atai Life Sciences Immatics Tango Therapeutics BGM Group Mind Medicine (MindMed) ArriVent BioPharma (NASDAQ:AVBP) and GENFIT (NASDAQ:GNFT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings. Do analysts rate AVBP or GNFT? ArriVent BioPharma currently has a consensus target price of $39.14, suggesting a potential upside of 104.72%. GENFIT has a consensus target price of $9.00, suggesting a potential upside of 131.30%. Given GENFIT's higher possible upside, analysts plainly believe GENFIT is more favorable than ArriVent BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ArriVent BioPharma 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00GENFIT 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer AVBP or GNFT? In the previous week, ArriVent BioPharma had 11 more articles in the media than GENFIT. MarketBeat recorded 13 mentions for ArriVent BioPharma and 2 mentions for GENFIT. ArriVent BioPharma's average media sentiment score of 1.42 beat GENFIT's score of 1.07 indicating that ArriVent BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GENFIT 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation and earnings, AVBP or GNFT? GENFIT has higher revenue and earnings than ArriVent BioPharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArriVent BioPharmaN/AN/A-$80.49M-$4.02-4.76GENFIT$76.77M2.53$1.63MN/AN/A Is AVBP or GNFT more profitable? GENFIT's return on equity of 0.00% beat ArriVent BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets ArriVent BioPharmaN/A -55.40% -51.97% GENFIT N/A N/A N/A Which has more volatility & risk, AVBP or GNFT? ArriVent BioPharma has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Comparatively, GENFIT has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500. Do institutionals and insiders hold more shares of AVBP or GNFT? 9.5% of ArriVent BioPharma shares are held by institutional investors. Comparatively, 2.2% of GENFIT shares are held by institutional investors. 18.6% of ArriVent BioPharma shares are held by insiders. Comparatively, 4.2% of GENFIT shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryArriVent BioPharma beats GENFIT on 7 of the 12 factors compared between the two stocks. Get GENFIT News Delivered to You Automatically Sign up to receive the latest news and ratings for GNFT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNFT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNFT vs. The Competition Export to ExcelMetricGENFITMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$203.11M$3.06B$5.66B$9.84BDividend YieldN/A2.28%3.93%4.04%P/E RatioN/A20.9283.2726.61Price / Sales2.53200.54451.26176.46Price / Cash58.0744.0537.7059.65Price / Book2.598.0710.556.59Net Income$1.63M-$53.98M$3.27B$266.12M7 Day Performance-9.85%-0.88%0.47%0.17%1 Month Performance-0.10%6.20%5.93%3.03%1 Year Performance-10.35%7.13%48.79%19.98% GENFIT Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNFTGENFIT1.9207 of 5 stars$3.89-4.2%$9.00+131.3%-11.4%$203.11M$76.77M0.00120Gap DownAVBPArriVent BioPharma2.3966 of 5 stars$19.24-1.5%$39.14+103.4%-28.6%$792.31MN/A-4.7940News CoverageAnalyst RevisionSANASana Biotechnology2.8785 of 5 stars$3.40+2.1%$8.00+135.3%-49.9%$791.90MN/A-3.21380GYREGyre Therapeutics1.3073 of 5 stars$7.85-3.6%N/A-43.6%$783.99M$102.19M785.7940News CoverageAnalyst ForecastAnalyst RevisionOCSOculis2.944 of 5 stars$18.06+0.9%$35.33+95.6%+34.0%$781.56M$780K-6.842News CoveragePositive NewsAnalyst ForecastDNAGinkgo Bioworks1.0499 of 5 stars$13.79+4.6%$8.50-38.4%+79.5%$780.25M$227.04M-2.35640Analyst UpgradeATAIatai Life Sciences3.4013 of 5 stars$4.05+4.4%$11.25+177.8%+252.3%$777.31M$310K-5.8780IMTXImmatics2.3943 of 5 stars$6.21-1.9%$14.67+136.2%-54.1%$769.41M$168.65M-9.55260High Trading VolumeTNGXTango Therapeutics1.8668 of 5 stars$7.22+6.6%$10.33+43.1%-39.7%$753.23M$42.07M-5.4390Insider TradeBGMBGM GroupN/A$8.15+7.7%N/A+12.9%$735.97M$25.10M0.00298Positive NewsMNMDMind Medicine (MindMed)2.463 of 5 stars$9.75+1.5%$24.71+153.5%+47.8%$731.21MN/A-6.3740Positive News Related Companies and Tools Related Companies ArriVent BioPharma Alternatives Sana Biotechnology Alternatives Gyre Therapeutics Alternatives Oculis Alternatives Ginkgo Bioworks Alternatives atai Life Sciences Alternatives Immatics Alternatives Tango Therapeutics Alternatives BGM Group Alternatives Mind Medicine (MindMed) Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNFT) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMy NEXT $1 Trillion PredictionJames Altucher is making his next trillion-dollar prediction — and this time, it’s not Apple. He believes Elon...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GENFIT S.A. Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share GENFIT With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
